{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"175"}],"units":"Participants"}],"description":"The ORR is defined as the percentage of participants who have at least a 30% reduction in the sum of diameters per RECIST (Version 1.1).","groups":[{"description":"Participants randomized to this arm received the study drug, tivozanib hydrochloride.","id":"OG000","title":"Tivozanib Hydrochloride"},{"description":"Participants randomized to this arm received the comparator drug, sorafenib.","id":"OG001","title":"Sorafenib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Every 8 weeks from date of randomization until disease progression (up to approximately 5 years)","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}